However, in the group of node-positive breast cancer patients PRL-3 expression was associated with a significantly worse DFS (66±7 months (95% CI 52–80) compared to patients with PRL-3-negative tumours (97±9 months (95% CI 79–115); P=0.032). Here, PTP4A3 is linked to neoplasm.